Crosstalk between triple negative breast cancer and microenvironment

Karly Smrekar; Artem Belyakov; Kideok Jin

doi:10.18632/oncotarget.28397

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

This article has an addendum. Addendum in: Oncotarget. 2023; 14:810-810.

Crosstalk between triple negative breast cancer and microenvironment

Karly Smrekar, Artem Belyakov and Kideok Jin _

PDF | Full Text | How to cite | Press Release

Oncotarget. 2023; 14:284-293. https://doi.org/10.18632/oncotarget.28397

Metrics: PDF 1324 views | Full Text 4842 views | ?

Abstract

Karly Smrekar1, Artem Belyakov1 and Kideok Jin1

1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Science, Albany, NY 12208, USA

Correspondence to:

Kideok Jin,

email:

[email protected]

Keywords: triple negative breast cancer; tumor microenvironment; current therapy

Received: January 13, 2023 Accepted: March 21, 2023 Published: March 31, 2023

Copyright: © 2023 Smrekar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Although many advances have been made in the treatment of breast cancer, for the triple negative breast cancer (TNBC) these therapies have not significantly increased overall survival. Tumor microenvironment (TME) plays an essential role to develop and control TNBC progression. Many preclinical and clinical studies are ongoing to treat patients with TNBC disease, but the effective therapies are currently not available. Here, we have reviewed recent progress in understanding of TNBC and advance in defining mechanisms of TNBC therapies and potential therapeutic strategies to overcome TNBC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28397

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Crosstalk between triple negative breast cancer and microenvironment

Abstract